An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer.

Trial Profile

An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Uprosertib (Primary)
  • Indications Gastric cancer; Oesophageal cancer; Ovarian cancer; Uterine cancer
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jan 2012 Actual patients number is 9 as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top